Related Experiment Video
Updated: Jan 9, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Targeted and Chemo-Free Approaches in HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis
Zaheer Qureshi1, Abdur Jamil2, Navkirat Kahlon3
1Department of Internal Medicine, School of Medicine at Quinnipiac University, Bridgeport, CT.
Objectives:
Human epidermal growth factor receptor-2 (HER2)-positive breast cancer is rapidly growing with poor outcomes if left untreated. Research evidence indicates that chemotherapy-free regimens can improve outcomes of HER2-positive early breast cancer while maintaining high oncogenic safety. The main objective of our study was to examine the efficacy and safety of chemotherapy-free regimens in patients with HER2-positive early breast cancer.
Methods:
A systematic literature search was conducted using the PubMed, CENTRAL, Google Scholar, and Embase databases to identify relevant randomized trials published until July 2024.
Results:
Five randomized trials, including 1489 patients with early-stage HER2-positive breast cancer, met the inclusion criteria for this meta-analysis. The pooled results showed that about 26.1% (182/698) of patients receiving chemo-free therapies achieve pathologic complete response (pCR). However, the subgroup analysis revealed that patients treated with trastuzumab plus pertuzumab and those treated with HER2-directed drugs plus endocrine therapy had significantly inferior pCR than those receiving chemotherapy combined with anti-HER2 drugs (OR: 0.22, P=0.0002 and OR: 0.25, P<0.00001). The meta-analytic results also demonstrated that patients receiving chemo-free therapies have high 3-year and 5-year invasive disease-free survival (iDFS) (95.40% and 85.71%) and 5-year event-free survival (EFS) (81.13). Regarding safety, the pooled results revealed that the discontinuation rates due to adverse events were statistically similar between the 2 groups (OR: 0.29, P=0.18).
Conclusions:
Chemotherapy-free regimens demonstrate promising responses and survival outcomes in patients with HER2-positive early breast cancer. However, the combination of anti-HER2 drugs with chemotherapy still demonstrates superior overall clinical outcomes.
Insights
Chemotherapy-free regimens show promise for HER2-positive early breast cancer, with good survival rates and similar safety profiles. However, chemotherapy combined with anti-HER2 drugs offers superior clinical outcomes.
Area of Science:
- Oncology
- Clinical Research
- Pharmacology
Background:
- HER2-positive breast cancer presents aggressive growth and poor prognosis without treatment.
- Chemotherapy-free regimens are emerging as a strategy to improve outcomes in early HER2-positive breast cancer.
- Assessing the efficacy and safety of these novel regimens is crucial for treatment optimization.
Purpose of the Study:
- To evaluate the efficacy and safety of chemotherapy-free regimens in patients with HER2-positive early breast cancer.
- To compare treatment outcomes between chemotherapy-free and conventional chemotherapy regimens.
- To analyze pathologic complete response (pCR), invasive disease-free survival (iDFS), and event-free survival (EFS).
Main Methods:
- A systematic literature search was performed across major databases (PubMed, CENTRAL, Google Scholar, Embase) up to July 2024.
- Included five randomized trials involving 1489 patients with early-stage HER2-positive breast cancer.
- Meta-analysis was used to pool data on treatment efficacy and safety outcomes.
Main Results:
- Approximately 26.1% of patients on chemotherapy-free regimens achieved pCR.
- Chemotherapy-free regimens showed high 3-year and 5-year iDFS (95.40%, 85.71%) and 5-year EFS (81.13%).
- Discontinuation rates due to adverse events were similar between chemotherapy-free and conventional groups (OR: 0.29, P=0.18), but pCR was inferior compared to chemotherapy plus anti-HER2 drugs.
Conclusions:
- Chemotherapy-free regimens demonstrate encouraging efficacy and survival benefits for HER2-positive early breast cancer.
- Despite promising safety, chemotherapy combined with anti-HER2 drugs remains superior in achieving overall clinical outcomes.
- Further research may refine chemotherapy-free strategies for specific patient populations.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers